Step 1: Understanding the Question:
The question asks which of these four chemotherapy drugs is known to cause cardiomyopathy as a characteristic adverse effect.
Step 2: Key Concept or Approach:
Adriamycin (doxorubicin) belongs to the anthracycline class of anticancer drugs. Anthracyclines generate free radicals and damage cardiac myocytes, producing a dose-dependent, often irreversible dilated cardiomyopathy. Because of this, patients on doxorubicin have their cumulative dose tracked and their left ventricular ejection fraction monitored during treatment.
Step 3: Working Through the Options:
Adriamycin is correct because anthracycline-induced cardiotoxicity is one of the best-known drug-organ toxicities in oncology. Carboplatin is a platinum agent whose dose-limiting toxicities are myelosuppression and nephrotoxicity, not the heart. Dactinomycin, an actinomycin antibiotic, mainly causes myelosuppression and mucositis. Etoposide, a topoisomerase II inhibitor, causes myelosuppression and hypotension if infused too fast, but not a cardiomyopathy pattern.
Step 4: Conclusion:
The correct answer is Adriamycin.